Induction of lacI mutations in Big Blue rats treated with tamoxifen and α-hydroxytamoxifen

Cancer Letters

Volumn 176, Issue 1, 2002, Pages 37-45

  Gamboa da Costa, Gonçalo ^a   Manjanatha, Mugimane G ^b   Matilde Marques, M ^a   Beland, Frederick A ^b  

^a INSTITUTO SUPERIOR TÉCNICO   (Portugal)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Hydroxytamoxifen; Big Blue rats; DNA adducts; LacI; Liver; Mutagenesis; Tamoxifen; Uterus

Indexed keywords

ALPHA (DEOXYGUANOSIN N 2 YL) N,N DINORTAMOXIFEN; ALPHA HYDROXYTAMOXIFEN; CARCINOGEN; DNA; DRUG METABOLITE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; NORTAMOXIFEN; TAMOXIFEN; TAMOXIFEN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA ADDUCT; ENDOMETRIUM CARCINOMA; FEMALE; GENE FREQUENCY; GENE INDUCTION; GENE MUTATION; GENOTOXICITY; LIVER; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SPLEEN LYMPHOCYTE; TRANSGENE; TREATMENT OUTCOME; UTERUS;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BACTERIAL PROTEINS; BODY WEIGHT; DNA ADDUCTS; ESCHERICHIA COLI PROTEINS; FEMALE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; LIVER; LIVER NEOPLASMS; LYMPHOCYTES; MUTAGENS; MUTATION; ORGAN SIZE; RATS; REPRESSOR PROTEINS; TAMOXIFEN; TIME FACTORS; UTERUS;

EID: 0037039714     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(01)00741-8     Document Type: Article

References (43)

1. Tamoxifen for early breast cancer: An overview of the randomised trials
2. Tamoxifen for prevention of breast cancer: Report of the National surgical adjuvant breast and bowel project P-1 study
3. Understanding the genotoxicity of tamoxifen?
4. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients
5. Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen
6. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen
7. Lack of genotoxicity of tamoxifen in human endometrium
8. 32P-post-labelling for tamoxifen-DNA adducts in the human endometrium
9. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats
10. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl CD(BR) rats
11. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat
12. Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen
13. DNA binding of tamoxifen and its analogues: Identification of the tamoxifen-DNA adducts in rat liver
14. Identification of the major tamoxifen-DNA adducts in rat liver by mass spectroscopy
15. N-Demethylation accompanies α-hydroxylation in the metabolic activation of tamoxifen in rat liver cells
16. Further characterization of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N,N-didesmethyltamoxifen
17. Characterization of the major DNA adduct formed by α-hydroxy-N-desmethyltamoxifen in vitro and in vivo
18. DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives
19. Mutational spectra of tamoxifen-induced mutations in the livers of lacI transgenic rats
20. Tamoxifen causes gene mutations in the livers of lambda/lacI transgenic rats
21. Tamoxifen induces G:C → T:A mutations in the cII gene in the liver of lambda/lacI transgenic rats but not at 5′-CpG-3′ dinucleotide sequences as found in the lacI transgene
22. Tamoxifen mutagenesis and carcinogenesis in livers of lambda/lacI transgenic rats: Selective influence of phenobarbital promotion
23. Short-term dosing of α-hydroxytamoxifen results in DNA damage but does not lead to liver tumours in female Wistar/Han rats
24. Uterine carcinoma in mice treated neonatally with Tamoxifen
25. Tamoxifen induces endometrial and vaginal cancer in rats in the absence of endometrial hyperplasia
26. Endometrial cancer induction by tamoxifen in the rat
27. Induction of endometrial cancer by tamoxifen in the rat
28. Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus
29. Determination of DNA damage in F344 rats induced by geometric isomers of tamoxifen and analogues
30. Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo
31. Production of 8-hydroxy-2′-deoxyguanosine in DNA by microsomal activation of tamoxifen and 4-hydroxytamoxifen
32. DNA cleavage and 8-hydroxydeoxyguanosine formation caused by tamoxifen derivatives in vitro
33. Mutagenic specificity of chemical carcinogens as determined by studies of single DNA adducts
34. Hydroxy derivatives of tamoxifen
35. α-Hydroxy-N,N-didesmethyltamoxifen, a proximate metabolite in the metabolic activation of tamoxifen to a carcinogen?
36. Induction of 6-thioguanine-resistant lymphocytes in Fischer 344 rats following in vivo exposure to N-ethyl-N-nitrosourea and cyclophosphamide
37. The effect of time after treatment, treatment schedule and animal age on the frequency of 6-thioguanine-resistant T-lymphocytes induced in Fischer 344 rats by N-ethyl-N-nitrosourea
38. +/- mice: Automated scoring of lymphocyte clones using a fluorescent viability indicator
39. DNA adduct formation and molecular analysis of in vivo lacI mutations in the mammary tissue of Big Blue® rats treated with 7,12-dimethylbenz[a]anthracene
40. 32P-postlabeling test for structurally diverse DNA adducts
41. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells
42. Comparison of hprt and lacI mutant frequency with DNA adduct formation in N-hydroxy-2-acetylaminofluorene-treated Big Blue® rats
43. 32P-postlabeling